+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global RNA Therapy Market by Technology (Enabled Technologies, Enabling Technologies), Indication (Cancer, Cardiovascular, Genetic Disorders), End User - Forecast 2024-2030

  • PDF Icon

    Report

  • 189 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968964
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The RNA Therapy Market grew from USD 2.18 billion in 2023 to USD 2.60 billion in 2024. It is expected to continue growing at a CAGR of 22.38%, reaching USD 8.98 billion by 2030.

These therapies treat various diseases and conditions by replacing faulty genes, silencing harmful gene expressions, or modulating cellular functions by targeting RNA molecules. Increasing investments in biotechnology startups, growing collaborations between academia and industry players, and an expanding portfolio of potential therapeutic targets for unmet medical needs drive the need for RNA therapies. Favorable regulatory policies for orphan drug designation and fast-track approvals have accelerated the clinical development of several RNA-based therapies. Delivery challenges associated with instability and rapid degradation of RNA molecules in vivo hampers market growth. Ongoing advancements by pharmaceutical companies to leverage cutting-edge technologies into novel RNA treatments for rare diseases with limited treatment options are expected to create opportunities for market growth.

Regional Insights

The RNA therapy market in the Americas is supported by a developed healthcare sector and supportive government programs, resulting in considerable commercialization of cutting-edge RNA therapies in the United States and Canada and the evolving pharmaceutical industry in South American countries. The governments in the Americas encourage technological advancements and research activities to provide a better healthcare system to people that contribute to overall economic growth and public welfare. The governments in the Asia-Pacific region's emerging and developed economies, such as Japan, India, China, and South Korea, encourage research and development of RNA therapies. Europe has significantly adopted RNA therapies owing to the rapid commercialization and acceptability of new devices and technologies, enabling healthcare professionals to use RNA therapies. On the other hand, the surging geriatric population in Europe is expected to increase the indication of several infectious and chronic disorders. As per the Population Reference Bureau (PRB), Russia, Germany, Italy, France, the UK, Spain, Turkey, Ukraine, Poland, Nigeria, and Iran are some countries that have a significant percentage of the population aged over 65 years. The rising indication of Europe's aging population and disorders necessitates efficient RNA therapies.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the RNA Therapy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Growing understanding of the role of RNA in disease pathology
  • Heightened demand for personalized medicine
  • Strategic alliances by pharmaceutical companies to foster novel RNA therapy development

Market Restraints

  • High costs associated with RNA therapy development processes

Market Opportunities

  • Increased investments by governments and private organizations in research and development activities
  • Pipelined clinical trials of RNA-based therapeutics

Market Challenges

  • Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines

Market Segmentation Analysis

  • Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.
  • Indication: Widespread applications of RNA therapy in genetic and cancer diseases.
  • End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the RNA Therapy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the RNA Therapy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing

ADARx Pharmaceuticals, a clinical-stage biotechnology firm specializing in next-generation RNA therapeutics, has completed a Series C funding round, raising USD 200 million. The funding enabled ADARx Pharmaceuticals to advance ADARx's clinical programs, including ADX-324 and ADX-038. The former represents a pioneering approach for treating hereditary angioedema (HAE), a rare genetic disorder characterized by painful, rapid swelling attacks that can be life-threatening. Additionally, the funding is estimated to facilitate the progress of an innovative pipeline comprising mRNA silencing or editing candidates to treat various diseases.

ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million

ReNAgade Therapeutics announced the funding of USD 300 million to revolutionize RNA therapeutics. This considerable funding underscores confidence in ReNAgade's potential to address vital limitations currently faced by RNA therapies while paving the way for pioneering treatment options and improved patient care. ReNAgade Therapeutics' entrance into the market with such robust financial backing highlights the continuing growth of next-generation healthcare solutions.

Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

Esperovax, an innovative biotechnology firm specializing in oral mRNA therapies, has entered into a strategic collaboration with Ginkgo Bioworks to advance the development of circular RNAs (circRNAs) for a wide range of therapeutic applications. The initial focus of the collaborative efforts between Esperovax and Ginkgo Bioworks enabled the designing and production of circRNAs carrying precise payloads that specifically target colorectal cancer. This pioneering methodology is intended to promote apoptosis or programmed cell death solely within malignant cells, leaving healthy tissue untouched. By leveraging Ginkgo Bioworks' cutting-edge platform for cellular engineering and Esperovax's expertise in oral mRNA biologics, the partnership seeks to bring forth novel circRNA-based treatment options that could revolutionize the field of oncology.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the RNA Therapy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Benitec Biopharma Limited, Biogen Inc., BioNTech SE, Cartesian Therapeutics, Inc., Cenix BioScience GmbH, Deep Genomics, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK PLC, Ionis Pharmaceuticals, Inc., Laronde, MiNA Therapeutics Limited, Moderna, Inc., NeuBase Therapeutics, Inc., Nordic Nanovector ASA, Novartis AG, Novo Nordisk A/S, Nutcracker Therapeutics, Inc., ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., and Triplet Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the RNA Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology- Enabled Technologies

  • Inhibition
  • Labeling
  • Linear amplification
  • Microarrays
  • Purification
  • qRT-PCR
  • Enabling Technologies

RNA Antisense Technologies

  • MicroRNA
  • Small interfering RNA
  • RNA Interference Technologies

Indication

  • Cancer
  • Cardiovascular
  • Genetic Disorders
  • Infectious Diseases
  • Kidney Diseases
  • Metabolic Disorders
  • Oncology
  • Retinal Diseases

End User

  • Academic Research
  • Diagnostics
  • Drug Discovery & Development

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing understanding of the role of RNA in disease pathology
5.1.1.2. Heightened demand for personalized medicine
5.1.1.3. Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
5.1.2. Restraints
5.1.2.1. High costs associated with RNA therapy development processes
5.1.3. Opportunities
5.1.3.1. Increased investments by governments and private organizations in research and development activities
5.1.3.2. Pipelined clinical trials of RNA-based therapeutics
5.1.4. Challenges
5.1.4.1. Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines
5.2. Market Segmentation Analysis
5.2.1. Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.
5.2.2. Indication: Widespread applications of RNA therapy in genetic and cancer diseases.
5.2.3. End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
5.8. Client Customization
6. RNA Therapy Market, by Technology
6.1. Introduction
6.2. Enabled Technologies
6.3. Enabling Technologies
7. RNA Therapy Market, by Indication
7.1. Introduction
7.2. Cancer
7.3. Cardiovascular
7.4. Genetic Disorders
7.5. Infectious Diseases
7.6. Kidney Diseases
7.7. Metabolic Disorders
7.8. Oncology
7.9. Retinal Diseases
8. RNA Therapy Market, by End User
8.1. Introduction
8.2. Academic Research
8.3. Diagnostics
8.4. Drug Discovery & Development
9. Americas RNA Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific RNA Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa RNA Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing
12.3.2. ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million
12.3.3. Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. RNA THERAPY MARKET RESEARCH PROCESS
FIGURE 2. RNA THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. RNA THERAPY MARKET DYNAMICS
FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 12. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. RNA THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY INHIBITION, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY INHIBITION, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY LABELING, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY LABELING, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY LINEAR AMPLIFICATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY LINEAR AMPLIFICATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY PURIFICATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY QRT-PCR, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY QRT-PCR, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY MICRORNA, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY MICRORNA, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL RNA THERAPY MARKET SIZE, BY RNA INTERFERENCE TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL RNA THERAPY MARKET SIZE, BY RNA INTERFERENCE TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL RNA THERAPY MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL RNA THERAPY MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL RNA THERAPY MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL RNA THERAPY MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL RNA THERAPY MARKET SIZE, BY RETINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL RNA THERAPY MARKET SIZE, BY RETINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 58. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 59. GLOBAL RNA THERAPY MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2023 (USD MILLION)
TABLE 60. GLOBAL RNA THERAPY MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2024-2030 (USD MILLION)
TABLE 61. GLOBAL RNA THERAPY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 62. GLOBAL RNA THERAPY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 63. GLOBAL RNA THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 64. GLOBAL RNA THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 65. AMERICAS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 66. AMERICAS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 67. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 68. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 69. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 70. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 71. AMERICAS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 72. AMERICAS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 73. AMERICAS RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 74. AMERICAS RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 75. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 76. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 77. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 78. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 79. ARGENTINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 80. ARGENTINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 81. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 82. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 83. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 84. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 85. ARGENTINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 86. ARGENTINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 87. ARGENTINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 88. ARGENTINA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 89. ARGENTINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 90. ARGENTINA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 91. BRAZIL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 92. BRAZIL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 93. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 94. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 95. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 96. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 97. BRAZIL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 98. BRAZIL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 99. BRAZIL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 100. BRAZIL RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 101. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 102. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 103. CANADA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 104. CANADA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 105. CANADA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 106. CANADA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 107. CANADA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 108. CANADA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 109. CANADA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 110. CANADA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 111. CANADA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 112. CANADA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 113. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 114. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 115. MEXICO RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 116. MEXICO RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 117. MEXICO RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 118. MEXICO RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 119. MEXICO RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 120. MEXICO RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 121. MEXICO RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 122. MEXICO RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 123. MEXICO RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 124. MEXICO RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 125. MEXICO RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 126. MEXICO RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 127. UNITED STATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 128. UNITED STATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 129. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 130. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 131. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 132. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 133. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 134. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 135. UNITED STATES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 136. UNITED STATES RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 137. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 138. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 139. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 140. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 142. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 144. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 146. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 148. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 150. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 152. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 154. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 155. AUSTRALIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 156. AUSTRALIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 157. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 158. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 159. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 160. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 161. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 162. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 163. AUSTRALIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 164. AUSTRALIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 165. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 166. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 167. CHINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 168. CHINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 169. CHINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 170. CHINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 171. CHINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 172. CHINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 173. CHINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 174. CHINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 175. CHINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 176. CHINA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 177. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 178. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 179. INDIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 180. INDIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 181. INDIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 182. INDIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 183. INDIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 184. INDIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 185. INDIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 186. INDIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 187. INDIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 188. INDIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 189. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 190. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 191. INDONESIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 192. INDONESIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 193. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 194. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 195. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 196. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 197. INDONESIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 198. INDONESIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 199. INDONESIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 200. INDONESIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 201. INDONESIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 202. INDONESIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 203. JAPAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 204. JAPAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 205. JAPAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 206. JAPAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 207. JAPAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 208. JAPAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 209. JAPAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 210. JAPAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 211. JAPAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 212. JAPAN RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 213. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 214. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 215. MALAYSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 216. MALAYSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 217. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 218. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 219. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 220. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 221. MALAYSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 222. MALAYSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 223. MALAYSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 224. MALAYSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 225. MALAYSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 226. MALAYSIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 227. PHILIPPINES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 228. PHILIPPINES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 229. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 230. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 231. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 232. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 233. PHILIPPINES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 234. PHILIPPINES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 235. PHILIPPINES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 236. PHILIPPINES RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 237. PHILIPPINES RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 238. PHILIPPINES RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 239. SINGAPORE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 240. SINGAPORE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 241. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 242. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 243. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 244. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 245. SINGAPORE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 246. SINGAPORE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 247. SINGAPORE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 248. SINGAPORE RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 249. SINGAPORE RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 250. SINGAPORE RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 251. SOUTH KOREA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 252. SOUTH KOREA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 253. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 254. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 255. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 256. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 257. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 258. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 259. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 260. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 261. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 262. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 263. TAIWAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 264. TAIWAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 265. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 266. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 267. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 268. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 269. TAIWAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 270. TAIWAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 271. TAIWAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 272. TAIWAN RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 273. TAIWAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 274. TAIWAN RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 275. THAILAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 276. THAILAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 277. THAILAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 278. THAILAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 279. THAILAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 280. THAILAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 281. THAILAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 282. THAILAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 283. THAILAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 284. THAILAND RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 285. THAILAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 286. THAILAND RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 287. VIETNAM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 288. VIETNAM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 289. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 290. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 291. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 292. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 293. VIETNAM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 294. VIETNAM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 295. VIETNAM RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 296. VIETNAM RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 297. VIETNAM RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 298. VIETNAM RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 313. DENMARK RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 314. DENMARK RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 315. DENMARK RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 316. DENMARK RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 317. DENMARK RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 318. DENMARK RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 319. DENMARK RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 320. DENMARK RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 321. DENMARK RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 322. DENMARK RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 323. DENMARK RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 324. DENMARK RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 325. EGYPT RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 326. EGYPT RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 327. EGYPT RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 328. EGYPT RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 329. EGYPT RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 330. EGYPT RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 331. EGYPT RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 332. EGYPT RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 333. EGYPT RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 334. EGYPT RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 335. EGYPT RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 336. EGYPT RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 337. FINLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 338. FINLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 339. FINLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 340. FINLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 341. FINLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 342. FINLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 343. FINLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 344. FINLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 345. FINLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 346. FINLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 347. FINLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 348. FINLAND RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 349. FRANCE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 350. FRANCE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 351. FRANCE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 352. FRANCE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 353. FRANCE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 354. FRANCE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 355. FRANCE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
TABLE 356. FRANCE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
TABLE 357. FRANCE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 358. FRANCE RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 359. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 360. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 361. GERMANY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 362. GERMANY RNA THERAPY MARKET SIZE, BY TE

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Benitec Biopharma Limited
  • Biogen Inc.
  • BioNTech SE
  • Cartesian Therapeutics, Inc.
  • Cenix BioScience GmbH
  • Deep Genomics
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GSK PLC
  • Ionis Pharmaceuticals, Inc.
  • Laronde
  • MiNA Therapeutics Limited
  • Moderna, Inc.
  • NeuBase Therapeutics, Inc.
  • Nordic Nanovector ASA
  • Novartis AG
  • Novo Nordisk A/S
  • Nutcracker Therapeutics, Inc.
  • ProQR Therapeutics N.V.
  • Sanofi S.A.
  • Silence Therapeutics PLC
  • Sirnaomics, Inc.
  • Triplet Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information